Clinical Trial Update: Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated a combination of docetaxel, cisplatin, pegfilgrastim, and erlotinib in patients with stage IIIB or stage IV non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Erlotinib hydrochloride (Erlotinib)
• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-06-28